Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases

References

• Roberts E, Frankel S. Gamma-aminobutyric acid in brain: its formation from glutamic acid. J Biol Chem. 1950;187:55–63.
   PubMed Web of Science ®Google Scholar
• Carlsson A. Thirty years of dopamine research. Adv Neurol. 1993;60:1–10.
   PubMedGoogle Scholar
• Catterall WA. Signaling complexes of voltage-gated sodium and calcium channels. Neurosci Lett. 2010;486 :107–116.
   PubMed Web of Science ®Google Scholar
• van Dyck CH. Anti-amyloid-beta; monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatry. 2018;83:311–319.
   PubMed Web of Science ®Google Scholar
• Vaikath NN, Hmila I, Gupta V, et al. Antibodies against alpha-synuclein: tools and therapies. J Neurochem. 2019;150:612–625.
   PubMed Web of Science ®Google Scholar
• Jensen TL, Gøtzsche CR, Woldbye DPD. Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord. Front Mol Neurosci. 2021;14:695937.
   PubMed Web of Science ®Google Scholar
• Bajan S, Hutvagner G. RNA-based therapeutics: from antisense oligonucleotides to miRNAs. Cells. 2020;9:137.
   PubMed Web of Science ®Google Scholar
• Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673–694.
   PubMed Web of Science ®Google Scholar
• Winkle M, El-Daly SM, Fabbri M, et al. Noncoding RNA therapeutics — challenges and potential solutions. Nat Rev Drug Discov. 2021;20:629–651.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Wang S, Vickers TA, et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol. 2017;35:230–237.
   PubMed Web of Science ®Google Scholar
• Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35:238–248.
   PubMed Web of Science ®Google Scholar
• Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24:374–387.
   PubMed Web of Science ®Google Scholar
• Vester B, Wengel J. LNA (Locked Nucleic Acid): high-affinity targeting of complementary RNA and DNA. Biochemistry. 2004;43:13233–13241.
   PubMed Web of Science ®Google Scholar
• Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7:187–195.
   PubMedGoogle Scholar
• Larsen HJ, Bentin T, Nielsen PE. Antisense properties of peptide nucleic acid. Biochim Biophys Acta. 1999;1489:159–166.
   PubMed Web of Science ®Google Scholar
• Amantana A, Iversen PL. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol. 2005;5:550–555.
   PubMed Web of Science ®Google Scholar
• McMahon BM, Mays D, Lipsky J, et al. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 2002;12:65–70.
   PubMedGoogle Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811.
   PubMed Web of Science ®Google Scholar
• Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2:711–719.
   PubMed Web of Science ®Google Scholar
• Ozcan G, Ozpolat B, Coleman RL, et al. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108–119.
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642–655.
   PubMed Web of Science ®Google Scholar
• Choung S, Kim YJ, Kim S, et al. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun. 2006;342:919–927.
   PubMed Web of Science ®Google Scholar
• Judge AD, Bola G, Lee ACH, et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006;13:494–505.
   PubMed Web of Science ®Google Scholar
• Manoharan M, Akinc A, Pandey RK, et al. Unique gene-silencing and structural properties of 2′-fluoro-modified siRNAs. Angew Chem Int Educ. 2011;50:2284–2288.
   PubMed Web of Science ®Google Scholar
• Allerson CR, Sioufi N, Jarres R, et al. Fully 2‘-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem. 2005;48:901–904.
   PubMed Web of Science ®Google Scholar
• Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 2003;13:83–105.
   PubMedGoogle Scholar
• Lima WF, Prakash T, Murray H, et al. Single-stranded siRNAs activate RNAi in animals. Cell. 2012;150:883–894.
   PubMed Web of Science ®Google Scholar
• Haraszti RA, Roux L, Coles AH, et al. 5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res. 2017;45:7581–7592.
   PubMed Web of Science ®Google Scholar
• Schlegel MK, Foster DJ, Kel’in AV, et al. Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA. J Am Chem Soc. 2017;139:8537–8546.
   PubMed Web of Science ®Google Scholar
• Janas MM, Schlegel MK, Harbison CE, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9:723.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood–brain barrier delivery. Drug Discov Today. 2007;12:54–61.
   PubMed Web of Science ®Google Scholar
• Haché M, Swoboda KJ, Sethna N, et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol. 2016;31:899–906.
   PubMed Web of Science ®Google Scholar
• Cordts I, Lingor P, Friedrich B, et al. Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disord. 2020;13:1756286419887616.
   Web of Science ®Google Scholar
• Bortolani S, Stura G, Ventilii G, et al. Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: transforaminal versus conventional approach. Neuromuscul Disord. 2019;29:742–746.
   PubMed Web of Science ®Google Scholar
• Nascene DR, Ozutemiz C, Estby H, et al. Transforaminal lumbar puncture: an alternative technique in patients with challenging access. Am J Neuroradiol. 2018;39:986–991.
   PubMed Web of Science ®Google Scholar
• Strauss KA, Carson VJ, Brigatti KW, et al. Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy. J Pediatr Orthop. 2018;38 e610–617. DOI:10.1097/BPO.0000000000001247.
   PubMed Web of Science ®Google Scholar
• Lazorthes Y, Sallerin-Caute B, Verdie J-C, et al. Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg. 1990;72:393–402.
   PubMed Web of Science ®Google Scholar
• Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation: Technology at the Neural Interface. 2017;20(2):96–132.
   PubMed Web of Science ®Google Scholar
• Draulans N, Vermeersch K, Degraeuwe B, et al. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clin Rehabil. 2013;27:1137–1143.
   PubMed Web of Science ®Google Scholar
• Jafar-nejad P, Powers B, Soriano A, et al. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Nucleic Acids Res. 2021;49:657–673.
   PubMed Web of Science ®Google Scholar
• Jimenez-Mateos EM, Engel T, Merino-Serrais P, et al. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med. 2012;18:1087–1094.
   PubMed Web of Science ®Google Scholar
• Cohen-Pfeffer JL, Gururangan S, Lester T, et al. Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol. 2017;67:23–35.
   PubMed Web of Science ®Google Scholar
• uniQure, Press Release. Accessed 15 Dec 2021 http://www.uniqure.com/patients/phase-1-2-clinical-trial-of-amt-130.php. .
   Google Scholar
• Padmakumar S, Jones G, Pawar G, et al. Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain. J Control Release. 2021;331:176–186.
   PubMed Web of Science ®Google Scholar
• Burgess A, Huang Y, Querbes W, et al. Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. J Control Release. 2012;163:125–129.
   PubMed Web of Science ®Google Scholar
• Guo Y, Lee H, Fang Z, et al. Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles. Sci Adv. 2021;7:eabf7390.
   PubMed Web of Science ®Google Scholar
• Godinho BMDC, Henninger N, Bouley J, et al. Transvascular delivery of hydrophobically modified siRNAs: gene silencing in the rat brain upon disruption of the blood-brain barrier. Mol Ther. 2018;26:2580–2591.
   PubMed Web of Science ®Google Scholar
• Reschke CR, Silva LFA, Vangoor VR, et al. Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy. Mol Ther. 2021;29:2041–2052.
   PubMed Web of Science ®Google Scholar
• Jensen SA, Day ES, Ko CH, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013;5:209ra152.
   PubMed Web of Science ®Google Scholar
• Zeniya S, Kuwahara H, Daizo K, et al. Angubindin-1 opens the blood–brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system. J Control Release. 2018;283:126–134.
   PubMed Web of Science ®Google Scholar
• Brichta L, Greengard P. Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update. Front Neuroanat. 2014;8:152.
   PubMed Web of Science ®Google Scholar
• von Bartheld CS, Bahney J, Herculano-Houzel S. The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting. J Comp Neurol. 2016;524:3865–3895.
   PubMed Web of Science ®Google Scholar
• Vocelle D, Chan C, Walton SP. Endocytosis controls siRNA efficiency: implications for siRNA delivery vehicle design and cell-specific targeting. Nucleic Acid Ther. 2019;30:22–32.
   PubMed Web of Science ®Google Scholar
• Deprey K, Batistatou N, Kritzer JA. A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics. Nucleic Acids Res. 2020;48:7623–7639.
   PubMed Web of Science ®Google Scholar
• Nair JK, Willoughby JLS, Chan A, et al. Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing. J Am Chem Soc. 2014;136:16958–16961.
   PubMed Web of Science ®Google Scholar
• Huang YY. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids. 2017;6:116–132.
   PubMedGoogle Scholar
• DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci. 2007;104:17204–17209.
   PubMed Web of Science ®Google Scholar
• Alterman JF, Hall LM, Coles AH, et al. Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain. Mol Ther Nucleic Acids. 2015;4:e266.
   PubMedGoogle Scholar
• Paterson J, Webster CI. Exploiting transferrin receptor for delivering drugs across the blood-brain barrier. Drug Discov Today Technol. 2016;20:49–52.
   PubMedGoogle Scholar
• Hammond SM, Abendroth F, Goli L, et al. Systemic antibody-oligonucleotide delivery to the central nervous system ameliorates mouse models of spinal muscular atrophy. bioRxiv. 2021 .July.29; 454272. DOI:10.1101/2021.07.29.454272
   Google Scholar
• Tai W, Gao X. Functional peptides for siRNA delivery. Adv Drug Deliv Rev. 2017;110–111:157–168.
   PubMed Web of Science ®Google Scholar
• Shabanpoor F, Hammond SM, Abendroth F, et al. Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy. Nucleic Acid Ther. 2017;27:130–143.
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448:39–43.
   PubMed Web of Science ®Google Scholar
• Kumar V, Patiyal S, Kumar R, et al. B3Pdb: an archive of blood–brain barrier-penetrating peptides. Brain Struct Funct. 2021;226:2489–2495.
   PubMed Web of Science ®Google Scholar
• Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75:193–208.
   PubMed Web of Science ®Google Scholar
• Gurung S, Perocheau D, Touramanidou L, et al. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal. 2021;19:47.
   PubMed Web of Science ®Google Scholar
• Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341–345.
   PubMed Web of Science ®Google Scholar
• Cooper JM, Wiklander PBO, Nordin JZ, et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord. 2014;29:1476–1485.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang X, Chen X, et al. Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia. Mol Ther Nucleic Acids. 2017;7:278–287.
   PubMedGoogle Scholar
• Cui G, Guo H-D, Li H, et al. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease. Immun Ageing. 2019;16:10.
   PubMed Web of Science ®Google Scholar
• Zhu X, Badawi M, Pomeroy S, et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J Extracell Vesicles. 2017;6:1324730.
   PubMed Web of Science ®Google Scholar
• Luan X, Sansanaphongpricha K, Myers I, et al. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017;38:754–763.
   PubMed Web of Science ®Google Scholar
• Tenchov R, Bird R, Curtze AE, et al. Lipid nanoparticles—from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15:16982–17015.
   PubMed Web of Science ®Google Scholar
• Hirunagi T, Sahashi K, Tachikawa K, et al. Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS. Mol Ther Nucleic Acids. 2021;24:1–10.
   PubMedGoogle Scholar
• Rungta RL, Choi HB, Lin PJ, et al. Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol Ther Nucleic Acids. 2013;2:e136.
   PubMedGoogle Scholar
• Inglut CT, Sorrin AJ, Kuruppu T, et al. Immunological and toxicological considerations for the design of liposomes. Nanomaterials. 2020;10:190.
   Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–829.
   PubMed Web of Science ®Google Scholar
• Barnaby SN, Sita TL, Petrosko SH et al. Therapeutic applications of spherical nucleic acids . Nanotechnology-based precision tools for the detection and treatment of cancer. eds. Mirkin CA, Meade TJ, Petrosko SH, et al. Switzerland: Springer International Publishing. 2015;23–50. DOI:10.1007/978-3-319-16555-4_2
   Google Scholar
• Sita TL, Kouri FM, Hurley LA, et al. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Proc Natl Acad Sci. 2017;114:4129–4134.
   PubMed Web of Science ®Google Scholar
• Xu F, Xia Q, Wang P. Rationally designed DNA nanostructures for drug delivery. Front Chem. 2020;8:751.
   PubMed Web of Science ®Google Scholar
• Tam DY, Weng-Thim Ho J, Chan MS, et al. Penetrating the blood–brain barrier by self-assembled 3D DNA nanocages as drug delivery vehicles for brain cancer therapy. ACS Appl Mater Interfaces. 2020;12:28928–28940.
   PubMed Web of Science ®Google Scholar
• NIH. Accessed 15 Dec 2021. https://www.ninds.nih.gov/About-NINDS/Impact/NINDS-Contributions-Approved-Therapies/Nusinersen-Spinraza®-–-Spinal-Muscular
   Google Scholar
• NIH. Accessed 15 Dec 2021. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet
   Google Scholar
• Biogen. Press Release. Accessed 05 Apr 2022. https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results
   Google Scholar
• Ionis. Accessed 15 Dec 2021. https://www.ionispharma.com/ionis-innovation/pipeline/
   Google Scholar
• Habtemariam BA, Karsten V, Attarwala H, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine–small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109:372–382.
   PubMed Web of Science ®Google Scholar
• Alnylam. Accessed 15 Dec 2021. https://www.businesswire.com/news/home/20210107005224/en/Alnylam-Reports-Positive-Topline-Results-from-HELIOS-A-Phase-3-Study-of-Vutrisiran-in-Patients-with-hATTR-Amyloidosis-with-Polyneuropathy
   Google Scholar
• Holm A, Løvendorf MB, Kauppinen S. Development of siRNA therapeutics for the treatment of liver diseases. In: Ditzel HJ, Tuttolomondo M, Kauppinen S, editors. Design and delivery of siRNA therapeutics. New York, NY, USA: Humana; 2021. p. 57–75. DOI:10.1007/978-1-0716-1298-9_5
   Google Scholar
• Ionis. Accessed 15 Dec 2021. https://www.ionispharma.com/medicines/akcea-ttr-l/
   Google Scholar
• Huntington's Disease Society of America. Accessed 19 Apr 2022. https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/
   Google Scholar
• Ionis. Accessed 15 Dec 2021. https://www.ionispharma.com/medicines/ionis-htt/
   Google Scholar
• Roche. Accessed 15 Dec 2021. https://www.roche.com/de/media/releases/med-cor-2021-03-22b.htm
   Google Scholar
• Kingwell K. Double setback for ASO trials in Huntington disease. Nat Rev Drug Discov. 2021;20:412–413.
   PubMed Web of Science ®Google Scholar
• Hagemann TL. Alexander disease: models, mechanisms, and medicine. Curr Opin Neurobiol. 2022;72:140–147.
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04849741
   Google Scholar
• Angelman Syndrome Foundation. Accessed 15 Dec 2021. https://www.angelman.org/for-parents/angelman-therapies/
   Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04428281
   Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04259281?term=GTX-102&draw=2&rank=1
   Google Scholar
• National Organization for Rare Disorders. Accessed 15 Dec 2021. https://rarediseases.org/rare-diseases/centronuclear-myopathy/
   Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04033159?term=NCT04033159&draw=2&rank=1
   Google Scholar
• MayoClinic. Accessed 15 Dec 2021. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447
   Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT03186989?term=NCT03186989&draw=2&rank=1
   Google Scholar
• Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions. ASN Neuro. 2009;1:e00002.
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT03976349?term=NCT03976349&draw=2&rank=1
   Google Scholar
• NHS. Accessed 15 Dec 2021. https://www.nhs.uk/conditions/multiple-system-atrophy/
   Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04165486?term=BIIB101&draw=2&rank=1
   Google Scholar
• Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43.
   PubMed Web of Science ®Google Scholar
• Limmroth V, Barkhof F, Desem N, et al. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology. 2014;83:1780–1788.
   PubMed Web of Science ®Google Scholar
• Shmuely S, Sisodiya SM, Gunning WB, et al. Mortality in Dravet syndrome: a review. Epilepsy Behav. 2016;64:69–74.
   PubMed Web of Science ®Google Scholar
• Dravet Syndrome News. Accessed 15 Dec 2021. https://dravetsyndromenews.com/2020/12/08/fda-allows-higher-dose-stk-001-for-adolescents-children-with-dravet-syndrome-in-monarch-trial/
   Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04740476
   Google Scholar
• Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017–3026.
   PubMed Web of Science ®Google Scholar
• Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890–897.
   PubMed Web of Science ®Google Scholar
• NHS Accessed 15 Dec 2021. https://www.nhs.uk/conditions/muscular-dystrophy/
   Google Scholar
• Angelini G, Mura G, Messina G. Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: the importance of the secondary therapies. Exp Cell Res. 2022;410:112968.
   PubMed Web of Science ®Google Scholar
• Sarepta. Accessed 15 Dec 2021. https://www.sarepta.com/products-pipeline/pipeline
   Google Scholar
• Stein CA. Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice. Mol Ther. 2016;24:1884–1885.
   PubMed Web of Science ®Google Scholar
• Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533–545.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Inotersen: first global approval. Drugs. 2018;78:1371–1376.
   PubMed Web of Science ®Google Scholar
• Yu RZ, Collins JW, Hall S, et al. Population pharmacokinetic–pharmacodynamic modeling of inotersen, an antisense oligonucleotide for treatment of patients with hereditary transthyretin amyloidosis. Nucleic Acid Ther. 2020;30:153–163.
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Accessed 15 Dec 2021. https://clinicaltrials.gov/ct2/show/NCT04136184?term=eplontersen&draw=2&rank=1
   Google Scholar
• Zlatev I, Castoreno A, Brown CR, et al. Reversal of siRNA-mediated gene silencing in vivo. Nat Biotechnol. 2018;36:509–511.
   PubMed Web of Science ®Google Scholar
• Crosby JR, Zhao C, Zhang H, et al. Reversing antisense oligonucleotide activity with a sense oligonucleotide antidote: proof of concept targeting prothrombin. Nucleic Acid Ther. 2015;25:297–305.
   PubMed Web of Science ®Google Scholar